Mitsui Chemicals, Inc. (MITUF)
USD 21.45
(0.0%)
USD 21.45
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1749.74 Billion | 1879.54 Billion | 1612.68 Billion | 1211.72 Billion | 1338.98 Billion | 1482.9 Billion |
| Cost of Revenue | 1378.94 Billion | 1498.05 Billion | 1233.94 Billion | 917.88 Billion | 1041.84 Billion | 1166.57 Billion |
| Gross Profit | 370.79 Billion | 381.49 Billion | 378.74 Billion | 293.84 Billion | 297.14 Billion | 316.33 Billion |
| Operating Expenses | 285.42 Billion | 263.14 Billion | 235.84 Billion | 216.94 Billion | 228.01 Billion | 210.36 Billion |
| Selling, General and Administrative Expenses | 240.73 Billion | 233.5 Billion | 195.59 Billion | 168.24 Billion | 191.85 Billion | 187.1 Billion |
| Research and Development Expenses | - | 43 Billion | 38.1 Billion | 33.8 Billion | 36.36 Billion | 35.79 Billion |
| Other Expenses | 14.01 Billion | - | - | - | -4.02 Billion | 585 Million |
| Cost and Expenses | 1664.37 Billion | 1761.2 Billion | 1469.78 Billion | 1134.82 Billion | 1269.85 Billion | 1376.94 Billion |
| Operating Income | 74.12 Billion | 90.72 Billion | 132.76 Billion | 81.12 Billion | 68.92 Billion | 93.42 Billion |
| Interest Expense | 14.66 Billion | 17.39 Billion | 12.21 Billion | 8.12 Billion | 9.15 Billion | 5.53 Billion |
| Income Tax Expense | 19.55 Billion | 27.14 Billion | 22.72 Billion | 10.02 Billion | 22.17 Billion | 18.77 Billion |
| Earnings before Tax | 73.33 Billion | 117.27 Billion | 141.27 Billion | 74.24 Billion | 68.46 Billion | 105.29 Billion |
| Net Income | 49.99 Billion | 82.93 Billion | 109.99 Billion | 57.87 Billion | 33.97 Billion | 76.11 Billion |
| Earnings Per Share Basic | 262.99 | 431.17 | 565.45 | 298.00 | 194.94 | 385.60 |
| Earnings Per Share Diluted | 262.99 | 431.17 | 565.45 | 298.00 | 194.94 | 385.60 |
| Weighted Average Shares Outstanding | 190.12 Million | 192.34 Million | 194.51 Million | 194.2 Million | 194.64 Million | 197.39 Million |
| Weighted Average Shares Outstanding (Diluted) | 190.12 Million | 192.34 Million | 194.51 Million | 194.2 Million | 194.64 Million | 197.39 Million |
| Gross Margin | 0.21 | 0.20 | 0.23 | 0.24 | 0.22 | 0.21 |
| EBIT Margin | 0.10 | 0.10 | 0.13 | 0.13 | 0.09 | 0.10 |
| Profit Margin | 0.03 | 0.04 | 0.07 | 0.05 | 0.03 | 0.05 |
| EBITDA | 181.14 Billion | 182.8 Billion | 216.98 Billion | 157.74 Billion | 121.03 Billion | 142.93 Billion |
| Earnings Before Tax Margin | 0.04 | 0.05 | 0.08 | 0.07 | 0.05 | 0.06 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | 1749.74 Billion | 475.21 Billion | 450.87 Billion | 415.73 Billion | 407.92 Billion | 1879.54 Billion |
| Cost of Revenue | 1378.94 Billion | 374.27 Billion | 358.96 Billion | 325.02 Billion | 320.68 Billion | 1498.05 Billion |
| Gross Profit | 370.79 Billion | 100.94 Billion | 91.9 Billion | 90.7 Billion | 87.24 Billion | 381.49 Billion |
| Operating Expenses | 285.42 Billion | 78.18 Billion | 63.13 Billion | 73.34 Billion | 73.35 Billion | 263.14 Billion |
| Selling, General and Administrative Expenses | - | 78.18 Billion | 64.51 Billion | 71.41 Billion | 68.54 Billion | - |
| Research and Development Expenses | - | 11.89 Billion | 11.3 Billion | 11.1 Billion | 10.4 Billion | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 1664.37 Billion | 452.45 Billion | 422.09 Billion | 398.37 Billion | 394.03 Billion | 1761.2 Billion |
| Operating Income | 85.37 Billion | 22.75 Billion | 25 Billion | 14.79 Billion | 10.8 Billion | 90.72 Billion |
| Interest Expense | 14.66 Billion | 6.71 Billion | 3.98 Billion | 2.86 Billion | 4.19 Billion | 17.39 Billion |
| Income Tax Expense | 19.55 Billion | 2.44 Billion | 8.44 Billion | 5.97 Billion | 2.69 Billion | 27.14 Billion |
| Earnings before Tax | 61.02 Billion | 11.27 Billion | 26.19 Billion | 18.82 Billion | 14.15 Billion | 117.27 Billion |
| Net Income | 49.99 Billion | 12.73 Billion | 16.57 Billion | 11.09 Billion | 9.59 Billion | 82.93 Billion |
| Earnings Per Share Basic | - | 67.00 | 87.16 | 58.36 | 50.46 | - |
| Earnings Per Share Diluted | - | 67.00 | 87.16 | 58.36 | 50.46 | - |
| Weighted Average Shares Outstanding | 190.12 Million | 190.12 Million | 190.13 Million | 190.14 Million | 190.06 Million | 192.34 Million |
| Weighted Average Shares Outstanding (Diluted) | 190.12 Million | 190.12 Million | 190.13 Million | 190.14 Million | 190.06 Million | 192.34 Million |
| Gross Margin | 0.21 | 0.21 | 0.20 | 0.22 | 0.21 | 0.20 |
| EBIT Margin | - | 0.10 | 0.11 | 0.09 | 0.08 | - |
| Profit Margin | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 | 0.04 |
| EBITDA | - | 47.84 Billion | 48.87 Billion | 37.96 Billion | 33.92 Billion | - |
| Earnings Before Tax Margin | 0.05 | 0.05 | 0.06 | 0.04 | 0.03 | 0.05 |
JBCHEPHARM
RFG
EQFN
300133
ROX
FNR